Chimeric Antigen Receptor (CAR)-T cell therapy is a pioneering technology that is successfully changing the way we think about the treatment of cancer, in particular blood...
Introduction Plant based protein products are already a well established destination in the supermarket aisle. Australia is reportedly the third fastest growing market for such...
Significant biosimilar activities this week include: 25 Jul 22 | US | FDA accepts ABLA for natalizumab biosimilar Sandoz announced that the FDA has accepted its ABLA for a...
We are proud to announce that Pearce IP and its CEO have been shortlisted for three awards at the APAC 2022 Women in Business Law Awards, with the winners to be announced on...
With great pleasure, we announce that our CEO and Executive Lawyer, Patent Attorney and Trade Mark Attorney Naomi Pearce has been named as one of the Australasian Lawyer’s Most...
The Full Court’s decision in Boehringer Ingelheim Animal Health USA Inc., v Intervet International B.V. [2022] FCAFC 88 is a useful analysis of the application of the “Cripps...
18 Jul 22 | MENA | Hikma and Celltrion enter into commercialisation agreement for YuflymaTM Hikma Pharmaceuticals announced that it has entered into a commercialisation agreement...
Globaltech Corporation Pty Ltd v Reflex Instruments Asia Pacific Pty Ltd [2022] FCA 797Date:Court:Judge:12 July 2022Federal Court of AustraliaJagot JBackground Globaltech...
11 Jul 22 | Overland ADCT commences trials of Zynlonta® in combination with rituximab in DLBCL Overland ADCT BioPharma announced the dosing of the first patient in China in its...
The key terms of an updated draft covid IP waiver have been released by the WTO. The draft includes terms intended to alleviate concerns of developed countries. However it will...
This week Pearce IP celebrated its 5th birthday, and received glowing reviews and rankings for the firm, and for three of its individual patent professionals by IAM Patent 1000....
04 Jul 22 | US | Xbrane Biopharma provides update on ranibizumab biosimilar Xbrane Biopharma confirmed that it will resubmit a BLA for its biosimilar to Lucentis® (ranibizumab)...
Pearce IP is proud to announce that our prosecution team has also been ranked among the best in Australia by Managing IP. This is in addition to the individual rankings of...
24 Jun 22 | AU | Samsung Bioepis commences AU revocation action against Fresenius Kabi adalimumab patent Samsung Bioepis filed a suit against Fresenius Kabi in the AU Federal...
We are proud to announce that the Pearce IP team of patent and trademark lawyers and attorneys has been selected as a finalist for the Lawyers Weekly Intellectual Property Team...
20 Jun 22 | CN | NMPA approves Innovent’s TYVYT® (sintilimab injection) Innovent Biologics and Eli Lilly announced that the CDE of China’s NMPA has approved the sNDA for TYVYT®...
Carefusion 303, Inc [2022] APO 40Date:Venue:Delegate:17 June 2022Australian Patent OfficeG PowellBackground Patent Application 2014268829 was filed by Carefusion 303, Inc on 16...
11 Jun 22 | Samsung Bioepis presents Ph III eculizumab data Samsung Bioepis presented data from its Ph III trials of SB12 (eculizumab biosimilar) in paroxysmal nocturnal...
Congratulations to CEO and Executive Naomi Pearce for being named as a finalist for the Lawyers Weekly Partners of the Year Awards 2022 in the category of Intellectual Property....
02 Jun 22 | Civica selects Profil as clinical trial partner for affordable insulin initiative Civica announced that is has selected Profil as its clinical trial partner to...
24 May 22 | BR | Shanghai Henlius Biotech signs license agreement for rituximab and trastuzumab biosims Shanghai Henlius Biotech announced that it has entered into a...
Astellas Pharma Inc. v Aragon Pharmaceuticals, Inc. [2022] APO 36Date:Venue:Delegate:23 May 2022Australian Patent OfficeF WhiteBackground Australian Patent Application 2018206695...
20 May 22 | EU | Prestige Biopharma (Roche/Genentech) | HD201, trastuzumab (Herceptin®) Prestige’s trastuzumab rejected by CHMP The CHMP recommended refusing the marketing...
16 May 22 | Alvotech (Janssen) | AVT04, ustekinumab, (Stelara®)Alvotech announces study results for AVT04, biosimilar ustekinumab Alvotech announced positive top-line results...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
